<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1549">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04459676</url>
  </required_header>
  <id_info>
    <org_study_id>ANG3777-ALI-201</org_study_id>
    <nct_id>NCT04459676</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia</brief_title>
  <official_title>A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angion Biomedica Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI Clinical Trial and Consulting Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Angion Biomedica Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the
      severity and progression of pulmonary and renal dysfunction and mortality in adult patients
      hospitalized with COVID-19 pneumonia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients alive, without the need for mechanical ventilation and free of the need for RRT (on an ongoing basis) at Day 28</measure>
    <time_frame>From the time of randomization until (Day 1) until death or until Day28, whichever comes first</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>ANG-3777 + SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ANG-3777 Administered IV for 30 min and SOC
Repeat within 24 hours after previous dosing for a total of 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard of Care + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care (SOC) + ANG-3777</intervention_name>
    <description>Standard of Care (SOC) + ANG-3777</description>
    <arm_group_label>ANG-3777 + SOC</arm_group_label>
    <other_name>BB3</other_name>
    <other_name>Hepatocyte growth factor mimetic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Of Care (SOC) + Placebo</intervention_name>
    <description>Standard Of Care + Placebo</description>
    <arm_group_label>Standard of Care + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is a male or nonpregnant female 18 years of age or older.

          2. Patient has a positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay
             for SARS-CoV-2 in a respiratory tract sample during the current hospital admission.

          3. Patient has pneumonia confirmed by chest imaging.

          4. Patient has score of 5 on the WHO's disease severity scale assessment 8-point Ordinal
             Scale at the time of randomization.

          5. Patient has ability to provide informed consent signed by study patient or legally
             acceptable representative.

          6. Patient has willingness and ability to comply with study-related
             procedures/assessments

        Exclusion Criteria:

          1. Has an active malignancy or history of solid or hematological malignancies within 5
             years prior to enrollment in the study. Patients who had basal or squamous cell
             carcinoma-in-situ of the skin that was diagnosed &gt; 2 years prior to the study
             enrollment and not currently being treated are eligible for study enrollment.

          2. Patient is pregnant or breast-feeding.

          3. Patient, in the opinion of the investigator, is unlikely to survive for ≥48 hours from
             the time of screening.

          4. Patient has any physical examination findings and/or history of any illness that, in
             the opinion of the study investigator, might confound the results of the study or pose
             an additional risk to the patient by their participation in the study.

          5. Patient with alanine aminotransferase (ALT) or aspartate transaminase (AST) &gt; 3x upper
             limit of normal (ULN) and/or total bilirubin &gt; 2xULN at baseline

          6. Patient requires treatment with the cytochrome P450 1A2 (CYP1A2) inhibitors,
             ciprofloxacin (Cipro®) and/or fluvoxamine (Luvox®)

          7. Patients participating in any other clinical trial with an investigational drug
             product or procedure

          8. Recipients of solid organ and/or hematopoietic cell transplantation

          9. Patient is known to have End Stage Renal Disease (ESRD) and was being treated with
             maintenance hemodialysis or peritoneal dialysis prior to the current hospitalization.

        Note: Patients who initiated RRT due to Acute Kidney Injury during their current
        hospitalization will be eligible for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Neylan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angion Biomedica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deb Gouveia</last_name>
    <phone>781-521-4286</phone>
    <email>dgouveia@angion.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Neylan, MD</last_name>
    <email>jneylan@angion.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPCLIN - Faculdade de Medicina da UNESP Campus de Botucatu</name>
      <address>
        <city>Botucatu</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP)</name>
      <address>
        <city>Ribeirão Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Guilherme Alvaro</name>
      <address>
        <city>Santos</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Escola Paulista de Medicina (Universidade Federal de São Paulo)</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Alemao Oswaldo Cruz</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Heliópolis-SP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 3, 2020</study_first_submitted>
  <study_first_submitted_qc>July 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Acute Lung Injury</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Respiratory Failure</keyword>
  <keyword>AKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

